69 results
8-K
EX-99.1
MOTS
Motus GI Holdings Inc
14 May 24
Motus GI Reports First Quarter 2024 Financial Results
4:21pm
of those terms, including without limitation, risks related to the continued impact of the COVID-19 pandemic, risks inherent in the development
424B3
MOTS
Motus GI Holdings Inc
2 Apr 24
Prospectus supplement
4:40pm
such as labor, freight and materials;
our ability to project in the short term the hospital medical device environment considering the global pandemic
8-K
EX-99.1
14vmdfuuvnih5y
18 Mar 24
Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results
4:05pm
424B3
5fk8u0h
9 Jun 23
Prospectus supplement
4:15pm
8-K
EX-99.1
8fs0427lvkca jke
22 May 23
Motus GI Announces $3.5 Million Private Placement
9:14am
8-K
EX-99.1
vr9 p3wv9kt
17 May 23
Motus GI Completes First Clinical Evaluation of New Pure-Vu® Gastro
8:35am
8-K
EX-99.1
qgl6fh6
11 May 23
Regulation FD Disclosure
7:05am
8-K
EX-99.1
e2jcm0z22si6imu
10 May 23
Motus GI Reports First Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
dsm350ai9h0n68 u47o
31 Mar 23
Motus GI Reports Fourth Quarter and Full Year 2022 Financial Results
4:05pm
8-K
EX-99.1
wy9gc ivm
21 Dec 22
Motus GI Announces Improvement of Pure-Vu® EVS System for Use in Upper Gastrointestinal (GI) Bleeding Procedures Following Successful Pre-Clinical Tests
8:12am
8-K
EX-99.1
ozh4sw4hw07erwx
14 Nov 22
Motus GI Reports Third Quarter 2022 Financial Results
4:14pm
8-K
EX-99.1
jzmfjtq25bslhksfof8s
24 Oct 22
Motus GI Announces Positive Clinical Data for Pure-Vu EVS in Three Poster
8:40am